An α-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients.
J Electrocardiol
; 51(1): 21-26, 2018.
Article
en En
| MEDLINE
| ID: mdl-28918212
ABSTRACT
BACKGROUND:
We tested the hypothesis that an alpha-glucosidase inhibitor (α-GI), miglitol, is effective in protecting the cardiovascular system in type 2 diabetes mellitus (T2DM).METHODS:
We studied 19 hospitalized heart disease patients with T2DM in whom we performed continuous glucose monitoring, Holter electrocardiogram, and ambulatory blood pressure (BP) monitoring simultaneously for 48h. The α-GI miglitol was administered for half of the study period by a cross-over fashion. T-wave alternans (TWA), a marker of future fatal arrhythmic events, was also analyzed by Holter ECG.RESULTS:
Of the 19 patients, the measures of glucose variability were significantly lower during miglitol therapy than in control period. BP variability was similar with/without miglitol. However, TWA was significantly lower during the miglitol period compared to control period (63±4.8 vs. 75.8±5.1µV, p=0.032).CONCLUSION:
An α-GI, miglitol, can reduce TWA by reducing the fluctuation of glucose in heart disease patients with T2DM.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Arritmias Cardíacas
/
Electrocardiografía Ambulatoria
/
1-Desoxinojirimicina
/
Diabetes Mellitus Tipo 2
/
Inhibidores de Glicósido Hidrolasas
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2018
Tipo del documento:
Article